No Data
No Data
Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Express News | Regulus Therapeutics Inc: Remain on Track for an End of Phase 1 Meeting With FDA by End of 2024
Express News | Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd)
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences